PLoS ONE (Jan 2014)

Evaluation of a new recombinant oncolytic vaccinia virus strain GLV-5b451 for feline mammary carcinoma therapy.

  • Marion Adelfinger,
  • Ivaylo Gentschev,
  • Julio Grimm de Guibert,
  • Stephanie Weibel,
  • Johanna Langbein-Laugwitz,
  • Barbara Härtl,
  • Hugo Murua Escobar,
  • Ingo Nolte,
  • Nanhai G Chen,
  • Richard J Aguilar,
  • Yong A Yu,
  • Qian Zhang,
  • Alexa Frentzen,
  • Aladar A Szalay

DOI
https://doi.org/10.1371/journal.pone.0104337
Journal volume & issue
Vol. 9, no. 8
p. e104337

Abstract

Read online

Virotherapy on the basis of oncolytic vaccinia virus (VACV) infection is a promising approach for cancer therapy. In this study we describe the establishment of a new preclinical model of feline mammary carcinoma (FMC) using a recently established cancer cell line, DT09/06. In addition, we evaluated a recombinant vaccinia virus strain, GLV-5b451, expressing the anti-vascular endothelial growth factor (VEGF) single-chain antibody (scAb) GLAF-2 as an oncolytic agent against FMC. Cell culture data demonstrate that GLV-5b451 virus efficiently infected, replicated in and destroyed DT09/06 cancer cells. In the selected xenografts of FMC, a single systemic administration of GLV-5b451 led to significant inhibition of tumor growth in comparison to untreated tumor-bearing mice. Furthermore, tumor-specific virus infection led to overproduction of functional scAb GLAF-2, which caused drastic reduction of intratumoral VEGF levels and inhibition of angiogenesis. In summary, here we have shown, for the first time, that the vaccinia virus strains and especially GLV-5b451 have great potential for effective treatment of FMC in animal model.